Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.2900 (-1.21%) ($5.2900 - $5.2900) on Fri. Jun. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.68% (three month average) | RSI | 60 | Latest Price | $5.2900(-1.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 2.3% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) KWEB(11%) IWO(9%) JETS(8%) IYT(7%) SIL(7%) | Factors Impacting ADMS price | ADMS will decline at least -1.84% in a week (0% probabilities). IWF(-80%) INDA(-56%) IVE(-49%) SPLV(-42%) SDY(-28%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.84% (StdDev 3.68%) | Hourly BBV | -0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.25(0.76%) | 10 Day Moving Average | $5.22(1.34%) | 20 Day Moving Average | $5.18(2.12%) | To recent high | -9.9% | To recent low | 5.6% | Market Cap | $150m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |